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Abstract
The multi-subunit mammalian NADH–ubiquinone oxidoreductase (complex I) is part of the mitochondrial electron transport chain and
physiologically serves to reduce ubiquinone with NADH as the electron donor. The three-dimensional structure of this enzyme complex
remains to be elucidated and also little is known about the physiological regulation of complex I. The enzyme complex in vitro is known to
exist as a mixture of active (A) and de-active (D) forms [Biochim. Biophys. Acta 1364 (1998) 169]. Studies are reported here examining the
effect of anoxia and reperfusion on the A/D-equilibrium of complex I in rat hearts ex vivo. Complex I from the freshly isolated rat heart or
after prolonged (1 h) normoxic perfusion exists in almost fully active form (87F2%). Either 30 min of nitrogen perfusion or global ischemia
decreases the portion of active form of complex I to 40F2%. Upon re-oxygenation of cardiac tissue, complex I is converted back
predominantly to the active form (80–85%). Abrupt alternation of anoxic and normoxic perfusion allows cycling between the two states of
the enzyme. The possible role in the physiological regulation of complex I activity is discussed.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
NADH–ubiquinone oxidoreductase (complex I) cata-
lyzes the first step in the mitochondrial electron transport
chain, the reduction of ubiquinone by NADH, which is
coupled to proton translocation across the inner mitochon-
drial membrane [1,2]. Complex I has a key role in supplying
the mitochondrial respiratory chain with reducing equiva-
lents since the majority of the electrons are provided by
NADH generated via reactions of the Krebs cycle. Bovine
complex I consists of at least 43 individual subunits [1,3].
The redox centers of the enzyme include one noncovalent
FMN moiety, as many as eight iron sulfur clusters [2,4], and
up to three detectable ubisemiquinone species [5]. Several
quite different catalytic mechanisms have been proposed
over the years for complex I [6,7]. Nevertheless, a full
understanding of the catalytic mechanism of complex I
remains to be elucidated.
In addition to its role in electron transport, recent
experimental observations suggest the involvement of com-
plex I or its subunits in other metabolic pathways. A small
nuclear encoded subunit of complex I (10 kDa) has been
identified as an acyl carrier protein [8]. Its removal makes
yeast respiration defective [9] and the subunit may be
involved in lipoic acid synthesis [10]. Complex I also may
play a key role in regulation of the permeability transition
pore of mitochondria [11] and is an important source of
reactive oxygen species (ROS) [12,13]. Recently, complex I
was linked to the apoptotic cell death pathway when GRIM-
19 was shown to be the 43rd subunit of bovine NADH–
ubiquinone oxidoreductase [3].
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Although little is known about the regulation of complex
I, it has been shown that the enzyme undergoes a slow
active/de-active transition in vitro [14]. It was proposed that
the transition between Active (A) and De-active (D) forms
might play a functional role in mammalian cell metabolism
[14,15]. The A-form catalyzes the physiologically relevant
rotenone-sensitive NADH–ubiquinone reductase reaction.
The D-form, by contrast, can be fully reduced by NADH
and oxidized by artificial electron acceptors, but is unable to
transfer electrons to ubiquinone [16]. The de-activation of
complex I is reversible, although transitions between the A-
and D-form require different conditions. De-activation, or
the A to D transition, is strongly temperature-dependent
(270 kJ/mol) and essentially does not occur at temperatures
below 20 jC (i.e., the enzyme remains active). Under
conditions where no enzyme turnover is permitted due to
complete reduction of the membrane ubiquinone pool
(regardless of whether the enzyme is reduced with NADH
or not), complex I is found largely in the de-activated form
[17]. Activation of the D-form of the enzyme is a result of
slow activating turnover(s), which includes fast reduction by
NADH and a slow (at least two orders of magnitude
compared to catalytic turnover) oxidation by quinone [17].
The rate of activation of the enzyme is less dependent upon
temperature (170 kJ/mol), and decreases at alkaline pH and
in the presence of divalent cations [18]. The A-form also is
not sensitive to sulfhydryl reagents, whereas the D-form is
specifically modified and inactivated by N-ethylmaleimide
(NEM) and other sulfhydryl agents [19].
The phenomenon of the reversible active/de-active
(AXD) transition described above has been shown for
isolated bovine complex I and for the enzyme in submito-
chondrial particles (SMP) [16,20]. Therefore, it is of interest
that recently, the transitions were also observed in isolated
mitochondria permeabilized with the channel-forming anti-
biotic alamethicin to deplete the mitochondria of endoge-
nous NADH [21]. However, it is still unknown whether
complex I undergoes the AXD transition in vivo. In cells
operating in normoxic conditions, where complex I cata-
lyzes steady-state NADH oxidation, it seems likely that the
majority of the enzyme would be in the active form [21].
Under hypoxic conditions such as global ischemia, where
lack of molecular oxygen leads to high levels of ubiquinol,
it is expected that complex I would be de-activated. Cardiac
function can be fully restored upon reperfusion if periods of
ischemia due to coronary occlusion are relatively short,
while longer periods of ischemia cause irreversible tissue
injury, and this damage can be exacerbated by reoxygena-
tion during reperfusion [22]. It has been shown in the
Langendorff-perfused rat heart that complex I is very
sensitive to this damage [23]. Anoxic perfusion had a
protective effect on complex I activity and subsequent oxy-
gen reperfusion did not cause further loss of its activity [24].
Thus, in order to study the AXD transition of complex I in
cardiac tissue, we subjected standard Langendorff-perfused
rat hearts to global ischemia or anoxic perfusion followed
by subsequent normoxic reperfusion. The data presented
here show that in freshly isolated rat heart, as well as after
60 min of normoxic perfusion, complex I is present in an
almost fully active state. Either global ischemia or anoxic
perfusion converts the majority of complex I to the de-active
state. Subsequent normoxic reperfusion returns complex I to
the predominantly active form. Therefore, these results
demonstrate that alternation of anoxic and normoxic con-
ditions does cause the AXD transition of complex I in a
whole organ preparation.
2. Materials and methods
2.1. Langendorff-perfused rat hearts
Male Sprague–Dawley rats (250–300 g) were anaesthe-
tized with sodium pentobarbital (60 mg/kg, IP) and anti-
coagulated with heparin (5000 USP units/kg, IP). The
thorax was opened and the heart excised and rapidly trans-
ferred into an ice-cold solution of 120 mM NaCl, 30 mM
KCl. The heart was then cannulated via the aorta and
perfusion started within 1 min in the Langendorff apparatus
with a constant pressure of 70 mm Hg and at a constant
perfusate temperature of 37 jC as previously described
[25]. Before any further treatment, the heart was equili-
brated for 5 min by perfusion with a modified Krebs–
Henseleit buffer (118 mM NaCl, 4.7 mM KCl, 2.5 mM
CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 24 mM
NaHCO3, 5.5 mM glucose, 5 mM sodium pyruvate, 0.5
mM Na2EDTA, pH 7.4) that was vigorously bubbled with
O2/CO2 (19:1, normoxia). Anoxia was induced by switch-
ing the perfusion to the same buffer saturated with N2/CO2
(19:1). Global ischemia was achieved by the cessation of
coronary flow.
2.2. Isolation of rat heart mitochondria
Immediately after being removed from the perfusion
apparatus, the heart was placed in isolation buffer (0.25
mM sucrose, 50 mM Tris–HCl (pH 7.8), 1 mM EDTA, 20
mM sodium azide, 20 mM succinate) that had been cooled
to 0–2 jC in a salt/ice bath. All subsequent steps were
performed at 0–2 jC, with all equipment and buffer
precooled and stored on ice. Any fatty tissue present on
the heart was removed and the heart was then minced into
2–3-mm pieces, isolation buffer added, and the tissue
homogenized with a glass homogenizer with a motor-
driven pestle. The homogenized preparation was then
centrifuged at 600g for 10 min. The supernatant con-
taining the mitochondria was carefully decanted and then
centrifuged at 8000g for 10 min. The pellet was then
suspended in the isolation buffer and washed two times by
centrifugation at 8000g for 10 min in the same buffer.
After the final centrifugation the washed mitochondria were
stored at 80 jC.
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2.3. Preparation of SMP
All steps were performed at 0–4 jC. The mitochondria
were resuspended in 4-ml of 0.125 mM sucrose, 20 mM
sodium azide, 20 mM succinate and the pH adjusted to 9.6
with ammonium hydroxide [26]. The mixture was sonicated
four times for 15 s with a cooling interval of 30 s and then
centrifuged at 35,000g for 15 min. The resulting super-
natant was centrifuged for 1.5 h at 130,000g. The pellet
containing the SMP was resuspended in 0.25 mM sucrose
and stored at 80 jC. Protein concentration was determined
with the BCA protein assay (Pierce, Rockford, IL) using
bovine serum albumin (BSA) as standard.
2.4. NADH–Q1 reductase activity
The standard assay mixture contained 0.25 mM sucrose,
20 mM Tris–HCl (pH 8.4), 0.2 mM EDTA, 0.5 Ag/ml
gramicidin D, 1 mg/ml BSA in a 1-ml cuvette. The NADH–
Q1 reductase reaction was assayed at 25 jC with 40 AM Q1
in the presence of 2 mM KCN after initiating the reaction by
addition of 150 AM NADH (e340=6.22 mM1 cm1). Since
only the A-form of complex I is able to catalyze quinone
reduction in the presence of divalent cations [18], 7 mM
MgCl2 was added to the assay to determine the fraction of
the A-form of complex I. The fraction of the A-form was
calculated as the ratio of NADH–Q1 reductase activity of as
isolated SMP to the activity of fully activated SMP. As
isolated SMP were assayed in the presence of 7 mM MgCl2.
Full activation of SMP was achieved by oxidation of 5 AM
NADH in a cuvette with Q1 before MgCl2 was added and
then 150 AM NADH initiated the reaction.
2.5. NADH–hexaaminoruthenium reductase activity
Activity was determined as described [27] at 25 jC in 2
ml of the standard assay mixture described above and with
0.5 mM NADH (e380=1.23 mM1 cm1) and 2 mM
Ru(NH3)6
3+ (Strem Chemicals, Newburyport, MA) in the
presence of 1 AM rotenone.
3. Results
We hypothesized that various complex I A/D equilibria
should be established in cardiac tissue associated with
different perfusion conditions. Thus, it was necessary to
find suitable conditions to preserve the A/D ratios by
preventing activation/de-activation of complex I throughout
SMP isolation. Such conditions have been established for in
vitro studies of bovine complex I [14] and initial isolation of
SMP relied on these procedures. De-activation of complex I
is completely prevented at low temperatures (0–2 jC) [16].
Therefore, as soon as perfusion ceased, the heart was
immediately placed in isolation medium that was cooled
to 0–2 jC in a salt/ice bath. Although the rate of the D-to-A
transition does not proceed at a significant rate at this
temperature [16], additional protection against redox-
dependent activation was thought to be necessary. Divalent
cations reversibly bind to the D-form and slow activation,
while the NADH–quinone reductase reaction catalyzed by
the A-form is not affected [18,20]. Therefore, 10 mM
MgCl2 was added to the mitochondrial isolation buffer in
order to determine if this would block any residual activa-
tion. This concentration of Mg2+ had no effect on normoxi-
cally perfused hearts, however, when the hearts were
subjected to 45 min of ischemia, complex I activity was
permanently decreased. Additional incubation of SMP with
EDTA did not restore the activity (data not shown). Another
approach to prevent complex I activation is to maintain the
quinone pool in a highly reduced state. Therefore, 20 mM
succinate and 20 mM sodium azide were used throughout
SMP isolation. Under these conditions, complex I activity of
SMP from normoxic or ischemic hearts was not affected.
Thus, sodium azide and succinate were used in the isolation
medium for mitochondria and SMP (see Materials and
methods).
To identify the A- and D-form of complex I, a simple
kinetic assay is routinely used. The A-form of the enzyme is
able to catalyze the NADH–quinone reductase reaction
while transition of the D-form to the A-form is characterized
by a pronounced lag-phase at alkaline pH in the presence of
divalent cations. Fig. 1 shows complex I activity catalyzed
by SMP isolated from Langendorff-perfused rat hearts
subjected to different perfusion conditions. The addition of
MgCl2 to the assay medium, prior to initiation of the
reaction with NADH, allows only the A-form to operate
(Fig. 1; traces 1a and b). Full activation of complex I is
achieved by oxidation of 5 AM NADH in the presence of
Fig. 1. Complex I activity of submitochondrial particles isolated from
Langendorff perfused rat hearts. NADH–Q1 reductase of SMP (5 Ag/ml
final concentration) was assayed as described in Materials and methods; 7
mM MgCl2 was added into the cuvette prior to initiation of the reaction by
150 AM NADH (traces 1a and 1b). SMP (5 Ag/ml) were fully activated by
oxidation of 5 AM NADH before 7 mM MgCl2 was added and the reaction
started with 150 AM NADH (traces 2a and 2b). SMP (1 mg/ml) were
thermally de-activated (15 min at 37 jC) and then assayed in the presence
of 7 mM MgCl2 (traces 3a and 3b).
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quinone before the addition of Mg2+ (Fig. 1; traces 2a and
b). The activation state of complex I from normoxically
perfused hearts determined in Fig. 1A is 87% (ratio of
activity from trace 1a to activity from trace 2a), which is
very similar to that from freshly isolated rat hearts seen in
Table 1. By contrast, prolonged anoxic perfusion with
nitrogen markedly reduces the portion of A-form of com-
plex I to only 40% (Fig. 1; ratio of activity from trace 1b to
activity from trace 2b). The SMP isolated from either
normoxic or hypoxic hearts can be fully de-activated by
incubation for 15 min at 37 jC (Fig. 1; traces 3a and b).
Such thermally deactivated SMP can be activated again by
preincubation with 5 AM NADH and quinone as shown for
traces 2a and b.
Another characteristic of de-active complex I is rapid and
irreversible inhibition of the enzyme by NEM, while the
active form is not sensitive to sulfhydryl agents under the
same conditions [14]. Fig. 2 represents the data comparing
the kinetic of SMP modification by NEM after prolonged
normoxic and anoxic perfusion of the hearts. Normoxic
SMP, as isolated (Fig. 1, trace 1a), were quite resistant to
treatments with 1 mM NEM (Fig. 2; closed circles, .).
When SMP were incubated for 15 min at 37 jC to convert
complex I into the de-active form (Fig. 1, trace 3a) prior to
the modification, the enzyme was rapidly inactivated by
NEM (Fig. 2; closed triangles, E). In contrast, the NEM
modification of anoxic SMP (Fig. 1, trace1b) showed partial
inhibition (Fig. 2; open diamonds, w ) of NADH–Q1 reduc-
tase that correlates to about 40% of complex I active form
remaining in anoxic SMP.
Table 1
Effect of anoxia/reperfusion on activities and activation state of complex I
from rat hearts
NADH–Ru3+ NADH–Q1
(+7 mM Mg2+)
Active-form
complex I
As isolatedb Pre-activatedc (%)
a
Amol/min/mg protein
Freshly
isolated
heart
13.7F0.06 1.16F0.03 1.33F0.03 87F2
60 min
normoxic
perfusion
14.7F0.10 1.20F0.02 1.40F0.02 86F2
30 min global
ischemia
12.7F0.02 0.43F0.02 1.14F0.03 38F2
+20 min
reperfusion
13.0F0.03 0.75F0.02 1.00F0.03 75F2
45 min global
ischemia
12.07F0.06 0.28F0.01 0.69F0.04 41F3
+20 min
reperfusion
12.26F0.02 0.40F0.01 0.58F0.03 69F3
60 min nitrogen
perfusion
14.1F0.16 0.52F0.01 1.34F0.04 39F2
+20 min
reperfusion
13.6F0.08 0.97F0.03 1.29F0.03 75F4
Each point is a meanFS.E. of three independent experiments.
a Activation status as ratio of the as isolated to pre-activated enzyme.
b Initial rate of the reaction determined with 7 mM MgCl2 started by
addition of NADH.
c SMP were pre-incubated with 5 AM NADH in the reaction medium,
then 7 mM MgCl2 was added, and the reaction started by NADH.
Fig. 2. Irreversible inhibition of complex I by NEM in submitochondrial
particles isolated from perfused rat hearts after 60-min normoxic or 60-min
anoxic perfusion. SMP (0.5 mg/ml) were incubated at 25 jC in the presence
of 1 mM NEM in the assay buffer (pH 7.8) for the time indicated on the
abscissa. The aliquots of the SMP suspension (5 Ag) were withdrawn and
NADH–Q1 reductase was determined at 25 jC (pH 7.8) with 150 AM
NADH and 40 AM Q1: (w ) 60-min nitrogen perfusion; (.) 60-min
normoxic perfusion; (E) SMP from normoxic perfused heart subjected to
15 min incubation at 37 jC, then cooled and incubated with 1 mM NEM.
One hundred percent activity corresponds to 1.4 Amol NADH/min/mg
protein.
Fig. 3. Effect of nitrogen perfusion and oxygen reperfusion of Langendorff
rat hearts on the activation state of complex I. Rat hearts were equilibrated
with normoxic buffer for 5 min after that the perfusion line was switched to
nitrogen saturated buffer (zero time) and the hearts were continuously
perfused (closed symbols, .). Dashed lines (open symbols, o) indicate
when normoxic reperfusion started after 15, 30, and 60 min of nitrogen
perfusion. Submitochondrial particles were isolated from each heart and
NADH–Q1 reductase were assayed in the presence of 7 mM MgCl2 as
described in Materials and methods. Each point is a meanFS.E. of three
independent experiments.
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Fig. 3 represents the time dependence of the A/D
equilibrium of SMP isolated from rat hearts upon anoxic
perfusion (closed circles, .). Although the apparent equili-
brium of 38F2% A-form is established by 30 min of the
perfusion, 15 min of anoxia already significantly reduces the
portion of A-form to 47F6%. When oxygen is re-intro-
duced to the anoxic cardiac tissue through normoxic reper-
fusion, the hearts resume beating and reach regular
rhythmical contraction within 5–7 min of reperfusion (data
not shown). Analysis of the activation state of complex I
following reperfusion (Fig. 3, open circles, o; dashed lines,
--) shows that following 15 min of anoxia, substantial
activation of complex I occurs within the first 5 min of
reperfusion and the initial activation state is reached in 20
min. The data in Fig. 3 show that complex I can also be
activated to approximately the same extent after 30 and 60
min of anoxia. Global ischemia (for 30 min) produces
similar results compared to anoxic perfusion (Table 1) since
both conditions eliminate oxygen supply from the tissue.
The data in Fig. 3 and Table 1 indicate that complex I can
alternate between the A-form and D-form depending upon
the state of oxygenation of the cardiac tissue. However, in
an agreement with previous studies [23], complex I can be
inactivated by prolonged global ischemia. This may be due
to different metabolic conditions established in ischemia and
anoxic perfusion: (i) while ischemia leads to substrate
deprivation and waste buildup; (ii) perfusion constantly
provides substrates for glycolysis and prevents accumula-
tion of its products.
In order to further investigate the ability of complex I to
undergo the AXD transition in ex vivo conditions, two
perfusion cycles were performed. Each cycle consisted of 15
min of anoxic and 20 min of normoxic perfusion. As seen in
Fig. 4, the cardiac tissue that had been through the first cycle
responded to the second nitrogen perfusion by a decrease of
the A-form fraction of complex I to a level similar to the
first cycle of anoxia. The final normoxic reperfusion again
caused significant activation of complex I. Thus, alternation
of normoxic/anoxic perfusion in rat hearts causes reversible
transition of complex I from highly active (normoxic) to
predominantly de-active (anoxic) state.
4. Discussion
The data presented show that either nitrogen perfusion or
global ischemia in isolated rat hearts significantly reduced
the fraction of the active form of complex I compared to
normoxic perfusion. The alternation between normoxic and
anoxic perfusion in isolated beating rat hearts resulted in
modulation of complex I between almost fully active
(normoxic) and predominately de-active (anoxic) forms. In
vitro data have shown that complex I within SMP can be
thermally de-activated to only 2–8% of the A-form [14–
16]. This communication reveals that SMP from nitrogen
perfused rat hearts retain about 40% of the A-form. It thus
becomes important to ascertain whether the higher activa-
tion levels of complex I found in SMP isolated from
perfused hearts reflect the true A/D equilibria or if the
higher activation levels observed might be due to the
experimental conditions. To preserve the equilibrium
between forms, isolation of SMP took into account proper-
ties of the AXD transition known from in vitro experiments
and was done in the presence of succinate and sodium azide
to maintain the quinone pool in the reduced state.
Nevertheless, we cannot exclude the possibility that
oxygen diffusion through the outer surface of the heart
during anoxic perfusion may have contributed to the higher
state of activation observed. Hearts were washed with eluted
buffer from the perfusate, but they were not placed in an
anoxic chamber. Since the conditions leading to de-activa-
tion of complex I produce high levels of mitochondrial
NADH [28,29], traces of oxygen in cardiac tissue could
provide slow turnovers of the respiratory chain which are
able to shift the A/D equilibrium to a higher activation state.
A simple experiment to test this suggestion was conducted
by imposing 30 min of global ischemia on rat heart in the
presence of 5 mM potassium cyanide in the perfusate buffer
to block cytochrome c-oxidase. Indeed, the activation state
of complex I determined in the presence of the respiratory
inhibitor decreased to 32% (data not shown) similar to the
state of activation seen for global ischemia alone (Table 1),
which is consistent with residual oxygen in the tissue being
responsible for the remaining active form of complex I.
Another possibility for a slow turnover of complex I during
anoxic conditions is the ability of succinate–ubiquinone
reductase (SQR, complex II) to act reversibly and reduce
fumarate by quinol. It has been suggested that anaerobic
metabolic pathways involving complexes I and II can
Fig. 4. Effect of alternation of anoxic and normoxic perfusion of
Langendorff rat hearts on activity and activation state of complex I. Rat
hearts were equilibrated with normoxic buffer for 5 min and then two cycles
each consisting of 15-min nitrogen and 20-min oxygen perfusion were
performed. Rotenone-sensitive NADH–Q reductase (.) and fraction of the
active form of complex I (o) were analyzed in SMP obtained from the
hearts. One hundred percent NADH–Q reductase activity corresponds to
1.4 Amol/min/mg protein. Each point is a meanFS.E. of three independent
experiments.
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account for maintenance of residual DAH during hypoxia
[30].
There are a number of low molecular weight ligands that
are known to affect the A/D equilibrium in vitro. It has been
suggested that millimolar levels of free Mg2+ and variable
concentrations of Ca2+ in the mitochondrial matrix should
preserve the D-form of complex I formed during hypoxia
even after re-oxygenation [21]. Indeed, as seen in Fig. 3,
establishing a new A/D equilibrium after re-oxygenation is
not instantaneous. It has been shown that the A- and D-form
of complex I exist in different conformations based on their
different affinities for sulfhydryl agents and on a change in
affinity for quinone binding site inhibitors [31]. For exam-
ple, rotenone preferentially binds to the A-form of the
enzyme (Ki=1 nM, versus 80 nM for the D-form) and
partially protects the complex I A-form from thermal de-
activation [31]. In addition, it was shown that when de-
activated SMP were incubated with rotenone, the A/D
equilibrium increased from 2% up to 50% active form. A
similar effect was demonstrated by incubating complex I
with Triton X-100 which is known to inhibit the enzyme
[32]. In agreement with the data above, when SMP had been
pre-incubated with NADH (conditions which shift the
equilibrium towards the A-form), photoaffinity labeling of
complex I with Q-site inhibitors increased PSST subunit
labeling, but decreased ND1 subunit labeling [33]. Arach-
idonic acid is a natural high affinity quinone site inhibitor of
complex I [34] and it is known that hypoxia significantly
increases the levels of this fatty acid in mitochondria [35].
Therefore, it is possible that arachidonic acid and/or other
long chain fatty acids may affect the A/D equilibrium by
binding differently to the A- and D-form of complex I.
In this work we have used an ex vivo experimental
model for the study of the complex I AXD transition where
a perfused heart retains physiological properties attributed
to live tissue. Thus, mitochondria maintain their integrity,
homeostasis, transmembrane potential, and respond to
metabolic changes in the cells. The observations reported
here that complex I in ex vivo conditions undergoes
changes in the A/D equilibria as a response to hypoxia/
normoxia do not yet prove the physiological relevance of
the phenomenon as a regulatory mechanism for NADH
oxidation. Nevertheless, the nature of the phenomenon
allows us to suggest at least two mechanisms for the
regulation of complex I involving the AXD transition.
One is the dependence of A/D equilibria on a combination
of factors such as temperature, oxygenation, mitochondrial
Ca2+ and Mg2+ concentration, and natural complex I Q-site
inhibitors. A second mechanism which should be consid-
ered is the selective covalent modification of the A- and D-
form, as is clearly seen for the highly reactive cysteine
residue present in the D-form [19]. Recently, cAMP-medi-
ated intracellular signal transduction through serine phos-
phorylation of the 18-kDa subunit of complex I has been
reported to affect enzyme activity [36]. Thus, triggering cell
signaling pathways may affect the A/D equilibrium and
study of such pathways may answer whether the AXD
transition controls mitochondrial respiration. Regulation of
complex I activity may have important consequences for
the production of ROS which might be formed as cardiac
tissue is re-oxygenated following a coronary occlusion.
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